Donation

ONS 2020 Header Image

We invite you to attend the symposium New Strategies for Multiple Myeloma Care: Case Studies for Nurses. We share patient case studies, the latest drug approvals, and clinical trial updates. 

This FREE Symposium was recently launched at the Oncology Nursing Society’s Bridge Virtual Conference, and is now available on-demand. 

New Strategies for Multiple Myeloma Care: Case Studies for Nurses
Part 1: Newly Diagnosed Multiple Myeloma (view only, no credit)

Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN®, FAAN; and Joseph D. Tariman, PhD, RN, ANP-BC, FAAN 

This activity on newly diagnosed multiple myeloma will include an overview of the disease, as well as current treatment workup and testing recommendations for multiple myeloma. Through the cases of June and Lisa, our faculty will explore transplant eligibility, induction, and maintenance therapy. 


New Strategies for Multiple Myeloma Care: Case Studies for Nurses
Part 2: Relapsed Multiple Myeloma (view only, no credit)

Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN®, FAAN; and Amy E. Pierre, RN, MSN, ANP-BC

This activity on relapsed multiple myeloma will include some recently approved drugs and dosage forms. Through the cases of Steve and Michelle, our faculty will review treatment considerations in the cases of early relapsed patients. 


New Strategies for Multiple Myeloma Care: Case Studies for Nurses
Part 3: Heavily Pretreated Multiple Myeloma and Drugs in Development (view only, no credit)

Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN®, FAAN; and Tiffany Richards, PhD, ANP-BC, AOCNP® 

This activity will focus on heavily pretreated multiple myeloma and drugs in development. Through the case of Carl, a patient who has received several multiple myeloma therapies over his 10-year history with the disease, our faculty will discuss clinical trial participation, and drugs in development.

 

VIEW SYMPOSIUM EARN UP TO 1.5 CNE           DOWNLOAD SLIDES

 


This activity is supported by educational grants from

Bristol Myers Squibb (formerly Celgene); GlaxoSmithKline; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Karyopharm Therapeutics Inc.; Oncopeptides, Inc.; and Takeda Oncology

 

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.